AU2013237497B2 - Carbohydrate-glycolipid conjugate vaccines - Google Patents

Carbohydrate-glycolipid conjugate vaccines Download PDF

Info

Publication number
AU2013237497B2
AU2013237497B2 AU2013237497A AU2013237497A AU2013237497B2 AU 2013237497 B2 AU2013237497 B2 AU 2013237497B2 AU 2013237497 A AU2013237497 A AU 2013237497A AU 2013237497 A AU2013237497 A AU 2013237497A AU 2013237497 B2 AU2013237497 B2 AU 2013237497B2
Authority
AU
Australia
Prior art keywords
carbohydrate
antigen
compound according
glucopyranose
spp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013237497A
Other languages
English (en)
Other versions
AU2013237497A1 (en
Inventor
Marco Cavallari
Gennaro De Libero
Peter H. Seeberger
Pierre STALLFORTH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsspital Basel USB
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Universitaet Basel
Universitaetsspital Basel USB
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/002277 external-priority patent/WO2013178236A1/en
Application filed by Universitaet Basel, Universitaetsspital Basel USB, Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Universitaet Basel
Publication of AU2013237497A1 publication Critical patent/AU2013237497A1/en
Application granted granted Critical
Publication of AU2013237497B2 publication Critical patent/AU2013237497B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2013237497A 2012-03-19 2013-03-19 Carbohydrate-glycolipid conjugate vaccines Active AU2013237497B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2012/054848 2012-03-19
EP2012054848 2012-03-19
AUPCT/EP2012/002277 2012-05-26
PCT/EP2012/002277 WO2013178236A1 (en) 2012-05-26 2012-05-26 Carbohydrate-glycolipid conjugate vaccines
PCT/EP2013/055719 WO2013139803A1 (en) 2012-03-19 2013-03-19 Carbohydrate-glycolipid conjugate vaccines

Publications (2)

Publication Number Publication Date
AU2013237497A1 AU2013237497A1 (en) 2014-10-02
AU2013237497B2 true AU2013237497B2 (en) 2016-05-12

Family

ID=47901120

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013237497A Active AU2013237497B2 (en) 2012-03-19 2013-03-19 Carbohydrate-glycolipid conjugate vaccines

Country Status (23)

Country Link
US (1) US10588962B2 (https=)
EP (1) EP2827899B1 (https=)
JP (2) JP5933106B2 (https=)
KR (1) KR101675657B1 (https=)
CN (1) CN104321079A (https=)
AR (1) AR090386A1 (https=)
AU (1) AU2013237497B2 (https=)
BR (1) BR112014023193A2 (https=)
CA (1) CA2866978C (https=)
CY (1) CY1116706T1 (https=)
DK (1) DK2827899T3 (https=)
ES (1) ES2551599T3 (https=)
HK (1) HK1205682A1 (https=)
HU (1) HUE028144T2 (https=)
IL (1) IL234604A (https=)
MX (1) MX337202B (https=)
PL (1) PL2827899T3 (https=)
PT (1) PT2827899E (https=)
RU (1) RU2649009C2 (https=)
SG (1) SG11201405646TA (https=)
SI (1) SI2827899T1 (https=)
TW (1) TWI633112B (https=)
WO (1) WO2013139803A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2851092A1 (en) * 2013-09-18 2015-03-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3
WO2016152980A1 (ja) * 2015-03-24 2016-09-29 国立大学法人岐阜大学 オリゴヌクレオチド誘導体及びそれを用いたオリゴヌクレオチド構築物並びにそれらの製造方法
CN106565800B (zh) * 2015-10-08 2019-08-13 中国人民解放军第二军医大学 三糖对甲氧基苯酚苷类化合物及其制备方法
TWI732825B (zh) * 2016-05-20 2021-07-11 日商王子控股股份有限公司 圖案形成用定向自組裝組成物、圖案形成用定向自組裝組成物用單體及圖案形成方法
CN106620682A (zh) * 2017-01-19 2017-05-10 华中师范大学 一种脂质体疫苗制剂及其用途和生产IgG抗体的方法
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
CN107955082B (zh) * 2017-12-11 2019-05-10 江南大学 幽门螺旋杆菌脂多糖外核心八糖的制备方法
CN115515965B (zh) * 2020-01-10 2024-12-24 南特大学 新型免疫刺激剂及其在免疫治疗中的用途
CN111760021B (zh) * 2020-05-18 2023-06-16 广州中医药大学(广州中医药研究院) 一种含有α-半乳糖神经酰胺类似物与糖抗原的缀合物及其制备方法和应用
CN111760020B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种缀合物及其制备方法和应用
KR102915939B1 (ko) * 2024-07-01 2026-01-21 코스맥스에이비 주식회사 피부상재균을 이용한 극성지질 발효물의 제조방법 및 이를 포함하는 화장료 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027685A2 (en) * 2004-09-07 2006-03-16 Novartis Vaccines And Diagnostics Srl Glycosylceramide adjuvant for saccharide antigens

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
FI20010118L (fi) * 2001-01-19 2002-07-20 Carbion Oy Uudet helicobacter pylori reseptorit ja niiden käyttö
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
WO2006093524A2 (en) * 2004-07-16 2006-09-08 The General Hospital Corporation Antigen-carbohydrate conjugates
CA2577009C (en) 2004-08-27 2017-05-02 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
US8022043B2 (en) 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
US7923013B2 (en) 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
WO2007051004A2 (en) * 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
CN102066394B (zh) * 2007-10-12 2015-04-01 路易吉·潘扎 用作免疫佐剂的糖脂的类似物
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
CN102355908B (zh) * 2009-01-23 2014-09-24 德克萨斯大学系统评论委员会 纳米粒子制备的糖脂免疫抗原
US8455565B2 (en) 2011-05-18 2013-06-04 3M Innovative Properties Company Disulfide monomers comprising ethylenically unsaturated groups suitable for dental compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027685A2 (en) * 2004-09-07 2006-03-16 Novartis Vaccines And Diagnostics Srl Glycosylceramide adjuvant for saccharide antigens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemistry & Biology 15, 654-664, July 21, 2008. *

Also Published As

Publication number Publication date
IL234604A (en) 2016-03-31
HK1205682A1 (zh) 2015-12-24
MX337202B (es) 2016-02-17
TW201343662A (zh) 2013-11-01
CA2866978C (en) 2019-01-29
JP5933106B2 (ja) 2016-06-08
CA2866978A1 (en) 2013-09-26
SG11201405646TA (en) 2014-10-30
US10588962B2 (en) 2020-03-17
KR101675657B1 (ko) 2016-11-11
HUE028144T2 (en) 2016-11-28
MX2014011242A (es) 2015-03-09
EP2827899B1 (en) 2015-08-05
ES2551599T3 (es) 2015-11-20
BR112014023193A2 (pt) 2017-08-01
JP2016183166A (ja) 2016-10-20
WO2013139803A1 (en) 2013-09-26
KR20140138996A (ko) 2014-12-04
RU2649009C2 (ru) 2018-03-29
TWI633112B (zh) 2018-08-21
AR090386A1 (es) 2014-11-05
JP2015514067A (ja) 2015-05-18
DK2827899T3 (en) 2015-10-26
EP2827899A1 (en) 2015-01-28
US20150238597A1 (en) 2015-08-27
SI2827899T1 (sl) 2015-11-30
RU2014142043A (ru) 2016-05-20
PT2827899E (pt) 2015-11-18
AU2013237497A1 (en) 2014-10-02
CN104321079A (zh) 2015-01-28
PL2827899T3 (pl) 2015-12-31
CY1116706T1 (el) 2017-03-15
JP6235648B2 (ja) 2017-11-22

Similar Documents

Publication Publication Date Title
AU2013237497B2 (en) Carbohydrate-glycolipid conjugate vaccines
CN111448205B (zh) 抗肺炎克雷伯菌的疫苗
CA2961694C (en) Vaccines against streptococcus pneumoniae serotype 8
KR102250099B1 (ko) 스트렙토코커스 뉴모니에 1형에 대한 합성 백신
JP2021504438A (ja) クレブシエラ ニューモニエ（Ｋｌｅｂｓｉｅｌｌａ ｐｎｅｕｍｏｎｉａｅ）に対するワクチン
WO2013178236A1 (en) Carbohydrate-glycolipid conjugate vaccines
JP2019504017A (ja) ストレプトコッカス ニューモニアエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）血清型２に対する合成ワクチン
WO2013041732A1 (en) Total synthesis and immunological evaluation of saccharide moieties of the lipopolysaccharide from neisseria meningitidis
CN113166186B (zh) 抗艰难梭状芽胞杆菌的稳定疫苗
KR102549847B1 (ko) 헤모필루스 인플루엔자 타입 b에 대항하는 백신으로서 안정한 가수분해-내성 합성 폴리리보실리비톨포스페이트 유도체
WO2022150924A1 (en) Process for the synthesis of reactive carbohydrates including antigen precursors for conjugation with a carrier material

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)